Inotiv (NASDAQ: NOTV) is one of 35 public companies in the “Commercial physical research” industry, but how does it compare to its peers? We will compare Inotiv to similar companies based on the strength of its analyst recommendations, valuation, institutional ownership, risk, earnings, profitability and dividends.
Valuation and Earnings
This table compares Inotiv and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Inotiv||$60.47 million||-$4.68 million||-82.86|
|Inotiv Competitors||$1.59 billion||$20.32 million||-6.36|
This is a summary of current ratings and price targets for Inotiv and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Commercial physical research” companies have a potential downside of 0.50%. Given Inotiv’s peers higher probable upside, analysts plainly believe Inotiv has less favorable growth aspects than its peers.
Insider and Institutional Ownership
20.2% of Inotiv shares are held by institutional investors. Comparatively, 48.1% of shares of all “Commercial physical research” companies are held by institutional investors. 11.5% of Inotiv shares are held by insiders. Comparatively, 14.3% of shares of all “Commercial physical research” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares Inotiv and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Inotiv has a beta of 2.12, suggesting that its share price is 112% more volatile than the S&P 500. Comparatively, Inotiv’s peers have a beta of 5.89, suggesting that their average share price is 489% more volatile than the S&P 500.
Inotiv peers beat Inotiv on 9 of the 10 factors compared.
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Receive News & Ratings for Inotiv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inotiv and related companies with MarketBeat.com's FREE daily email newsletter.